Navigation Links
Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Date:9/26/2007

RX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX- 0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

About Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

Japan Tobacco Inc. is the world's third largest international manufacturer of tobacco products. Since its privatization in 1985, JT has actively diversified its operations into pharmaceuticals and foods. JT entered into the pharmaceutical business in 1987 and established the Central Pharmaceutical Research Institute in 1993. JT is currently engaged in the research and development of new drugs in various areas such as glucose and lipid metabolism, anti-virus, immune disorders and inflammation, and bone metabolism. The company's net sales were 4.769 trillion yen in the fiscal year that ended March 31, 2007.

Torii Pharmaceutical Co., Ltd., established in 1921, has manufactured and distributed ethical pharmaceutical products. In 1998, Torii became a member of the JT Group. To maximally leverage the synergy of the Group,
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. WARF enters licensing agreements for stem cell products
2. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
3. Software company enters health space with RFID solutions on hold
4. Lucigen Corp. enters global licensing agreement
5. Call centers and customer service: The good, the bad, and the clueless
6. GE Healthcare enters agreement with Canadian health authority
7. Data centers: Buyers beware of over-hyped facilities
8. Data centers: Blowing smoke and raising red flags
9. Prodesse enters patent agreement with Roche
10. UW-Madison enters Kauffman grant competition
11. Applied Technology Centers to aid printing and manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... MA (PRWEB) May 22, 2013 Cambridge ... present at last week’s “Data Demonstration Day” on Capitol Hill, ... Semantics joined EMC, Google, Microsoft and others to showcase how ... proposed Digital Accountability and Transparency Act (DATA Act). , Originally ... Issa (R-CA) and Sen. Mark Warner ...
(Date:5/22/2013)... The Conference Forum announced ... Advance Clinical Trials conference taking place on September 19-20 ... , Disruptive thinkers from Novartis, Pfizer, Eli Lilly, ... approaches to reduce expensive infrastructure, engage patients and generate ... be big, or novel, or it must change the ...
(Date:5/22/2013)... YORK , May 22, 2013   ... the development of disease modifying therapeutics for Alzheimer,s ... the completion of its Series B financing, which ... and warrants that would represent approximately $2.8M in ... and new investors supported the raise. ...
(Date:5/22/2013)... May 22, 2013  Empire Genomics announced today ... patent pending novel genomic biomarker from Cornell University ... that could help in diagnosing and determining treatment ... Neuroendocrine prostate cancer (NEPC) is a ... arise de novo, but more commonly arises after ...
Breaking Biology Technology:Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2
... Remedy Informatics, the leading provider of registries for Life ... Providence Health & Services, has selected Remedy,s Mosaic(TM) ... Telestroke Network to improve patient outcomes . ... excited to work with Providence, and to support their ...
... (NASDAQ: CPHD ) today announced that, together ... Jersey (UMDNJ), it has received a grant from the ... amplification methods for highly-sensitive detection of bloodstream bacteria using ... The $1.3 million grant is for the first year ...
... BOSTON, Massachusetts, March 20, 2012 Heptares ... an operating company of Shire PLC (LSE: SHP, NASDAQ: ... has exercised its exclusive option to license a novel ... is currently in preclinical development. Adenosine A 2A ...
Cached Biology Technology:Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 2Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 3Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 2Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 3Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 4Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 2Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 3
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
(Date:5/20/2013)... the effect of physical education (PE) on child weight, ... increasing the amount of time that elementary schoolchildren spent ... The study represents some of the first evidence of ... is forthcoming in the Journal of Health Economics ... can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3Gym class reduces probability of obesity, study finds for first time 2
... planning of the preparatory activities for a new tentative ... satellite. On 7 September, preparatory activities for the ... Russia were stopped by Eurockot due to an anomaly ... and navigation subsystem of the launcher,s Upper Stage Breeze ...
... a highly selective behavior towards odor stimuli. A ... olfactory stimulus is often not sufficient for immediate ... Interestingly, the behavior differed between investigated D. ... mangos) were preferred by most flies, whereas artificial ...
... 1 OCTOBER 2008 Not only are more than ... Brown Convention Center, beginning this weekend, to participate in ... but they are bringing focus to issues of local ... theme of "Celebrating the International Year of Planet Earth," ...
Cached Biology News:What is wild? Odor attraction among different wildtype Drosophila 2What is wild? Odor attraction among different wildtype Drosophila 3Earth scientists keep an eye on Texas 2Earth scientists keep an eye on Texas 3Earth scientists keep an eye on Texas 4Earth scientists keep an eye on Texas 5
...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
Mouse monoclonal antibody raised against a partial recombinant PRG4. NCBI Entrez Gene ID = PRG4...
Biology Products: